Should You Buy ACB Stock Amid Curaleaf's Hostile Takeover Attempt?

Still, the stock jumped nearly 21% as investors weighed the possibility of a deal that could create a major global cannabis player.

What’s on the Table & Why ACB Matters

Under the proposed deal, Curaleaf would offer Aurora shareholders US$4 per share, consisting of 0.3463 Curaleaf shares and US$0.75 in cash. The proposal represents a 45% premium to Aurora’s 30-day volume-weighted average price. Curaleaf has also proposed a cap of US$5 per Aurora share, meaning the final value of the consideration would be subject to movements in Curaleaf’s stock price.

The strategic rationale behind Curaleaf's interest appears fairly straightforward. Aurora has transformed itself into a predominantly medical cannabis company, with international medical cannabis revenues rising 17% year over year in the first quarter of fiscal 2027 (year ended March 2027). International markets accounted for about 64% of total revenues during the quarter, underscoring the growing importance of ACB’s overseas operations.

Curaleaf believes the combination would create a stronger global cannabis platform by bringing together complementary assets. In particular, it is seeking to leverage Aurora’s EU-GMP-certified cultivation and manufacturing capabilities alongside its own processing and international distribution infrastructure. ACB recently acquired the 59,000-square-foot Safari Flower Company facility, which adds further EU-GMP capacity to support demand in international medical cannabis markets.

Importantly, the proposed combination would also give ACB shareholders exposure to Curaleaf’s U.S. cannabis operations, providing a potential route into the world's largest cannabis market. For Aurora, this could broaden its market opportunity without requiring the company to build a standalone U.S. platform.

The proposed transaction could also give Curaleaf a meaningful edge over rivals seeking to strengthen their international medical cannabis platforms. For instance, Tilray Brands TLRY has been expanding its medical cannabis footprint, including through its June acquisition of HelloMD to strengthen patient access in Canada and its April acquisition of Lyphe to expand its UK medical cannabis platform. Curaleaf's proposed acquisition of Aurora would add an established international medical cannabis business and additional EU-GMP capacity to its global network.

Curaleaf estimates that the combined company could generate more than US$1.5 billion in revenue and nearly US$350 million in adjusted EBITDA, while delivering at least US$40 million in annual cost synergies.

Aurora’s Response to Curaleaf’s Takeover Bid

Aurora has disputed Curaleaf’s characterization of its approach and said its board is carefully reviewing the proposal. The company confirmed that it received letters from Curaleaf, dated June 23 and July 7, outlining proposals to acquire all of Aurora’s outstanding shares. Aurora noted that only the July 7 letter included financial terms and did not specify the proposed mix of cash and shares.

Aurora also disputed Curaleaf’s assertion that it had refused to engage on a potential transaction. Per the company, its lead independent director continued to correspond with Curaleaf’s CEO, including as recently as July 24, while communicating that ACB remained focused on executing its business plan over the short to medium term. The company said it did not discourage continued dialogue between the two parties.

The Aurora board intends to form a special committee of independent directors to consider Curaleaf’s proposal and determine the course of action that is in the best interest of the company and its stakeholders. No decision has been made regarding the proposal, and Aurora continues to operate its business while executing its existing strategic plans.

ACB Stock Performance & Valuation

Year to date, shares of Aurora have lost over 17% compared with the industry‘s 16% decline.

Image Source: Zacks Investment Research

Estimate movements for fiscal 2026 and 2027 have improved significantly in the past 7 days.

Image Source: Zacks Investment Research

How to Play ACB Stock?

Investors should consider Aurora Cannabis based on its long-term fundamentals rather than rely solely on the ongoing acquisition talks. Although Curaleaf has announced its intention to launch a takeover bid, there is no certainty that the proposed transaction will be completed, and the offer could ultimately be withdrawn or fail to receive the necessary approvals.

Nevertheless, Aurora continues to offer exposure to the growing medical cannabis market, with its international operations becoming an increasingly important contributor to revenues. The company’s continued focus on medical cannabis and expansion across international markets support its long-term growth prospects. Improved bottom-line estimates suggest optimistic analyst outlook toward the stock.

The potential Curaleaf deal should therefore be viewed as an additional catalyst rather than the primary investment thesis. With Aurora’s standalone prospects remaining favorable, the company sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Beyond Nvidia: AI's Second Wave Is Here

The AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. AI’s second wave is moving from infrastructure to implementation and these companies are at the forefront of this transition, positioned to become what Amazon and Google were to the internet era.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research